← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV28행 · 1개 프로그램
OverviewMoAPK/PDToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 3
Recombinant Interferon Alfa-2b (Recombinant Interferon Alfa-2b)
Merck Sharp & Dohme LLC·HER2
83 trials·t½ 57 h
Overview
Program
Recombinant Interferon Alfa-2b
Overview
Company
Merck Sharp & Dohme LLC
Overview
Modality
CGT
Overview
Target
HER2
Overview
Indication
Recurrent Melanoma; Stage IIIA Cutaneous Melanoma AJCC v7
Overview
Phase
PHASE_3
Overview
Status
RECRUITING
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
MoA
Mechanism
(MoA) in patients with advanced solid tumors
MoA
Biomarker
biomarkers and clinical biochemical indicators were assessed during follow-up
PK/PD
Half-life
57 h
PK/PD
Species
Mouse
PK/PD
Animal (cat.)
Mouse
PK/PD
Experiment
Pharmacokinetic
Toxicology
Species
Mouse
Toxicology
Animal (cat.)
Mouse
Toxicology
Major finding
thrombocytopenia (28
Clinical
Safety signal
thrombocytopenia (28
Clinical
Selected reported efficacy
ORR 2%
Clinical
Reported ORR
2%
Clinical
Reported PFS
16.6
Clinical
Reported OS
35.2
Clinical
Result source
ClinicalTrials.gov NCT00569127
Clinical
Program phase
PHASE_3
Clinical
Trial ref
NCT00569127